Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus BUDESONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus BUDESONIDE.
ARMONAIR RESPICLICK vs BUDESONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armonair Respiclick is a metered-dose inhaler containing beclomethasone dipropionate, a corticosteroid. It exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine release in the airways.
Budesonide is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting pro-inflammatory cytokines and leukocyte migration.
Inhaled: 55 mcg to 113 mcg per actuation, 1 to 2 actuations twice daily. Maximum 2 actuations twice daily.
Inhaled: 400-800 mcg/day in 2 divided doses for asthma; oral controlled ileal release: 9 mg once daily for Crohn's disease; intranasal: 256 mcg/day in 2 sprays per nostril once daily for allergic rhinitis.
None Documented
None Documented
Clinical Note
moderateBudesonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin."
Clinical Note
moderateBudesonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin."
Clinical Note
moderateBudesonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin."
Clinical Note
moderateBudesonide + Trovafloxacin
Terminal elimination half-life is approximately 26 hours (range 21-36 hours). This supports once-daily dosing for bronchodilation in COPD.
2-3.6 hours (terminal elimination half-life); due to high hepatic clearance, systemic half-life is short, limiting systemic exposure.
Renal: approximately 99% of an administered dose is excreted in urine, with 95% as conjugated metabolites and 2% as free arformoterol. Fecal: approximately 1%. Biliary: negligible.
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (~60%) and urine (~10-15%). Renal excretion of unchanged drug is negligible (<2%).
Category C
Category A/B
Inhaled Corticosteroid
Inhaled Corticosteroid
"The risk or severity of adverse effects can be increased when Budesonide is combined with Trovafloxacin."